{"transactions":[{"id":3372072,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153826,"kind":"organization","name":"Celgene European Investment Co LLC","position":2,"cik":"0001577650","reported_name":"Celgene European Investment Co LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153827,"kind":"organization","name":"Celgene Switzerland LLC","position":3,"cik":"0001661486","reported_name":"Celgene Switzerland LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153828,"kind":"organization","name":"Celgene Alpine Investment Co., LLC","position":4,"cik":"0001581774","reported_name":"Celgene Alpine Investment Co., LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-11-14T16:06:15.000Z","date":"2019-11-12","kind":"purchase","acquired":true,"shares":403225,"price":31,"value":12499975.0,"ownership":{"direct":true},"balance_after":1777824,"source":{"system":"sec-edgar","filing":"0001104659-19-064171","document":"tm1922788d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000110465919064171/tm1922788d1_4.xml","form_type":"4"}},{"id":4084023,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153827,"kind":"organization","name":"Celgene Switzerland LLC","position":2,"cik":"0001661486","reported_name":"Celgene Switzerland LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153828,"kind":"organization","name":"Celgene Alpine Investment Co., LLC","position":3,"cik":"0001581774","reported_name":"Celgene Alpine Investment Co., LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153826,"kind":"organization","name":"Celgene European Investment Co LLC","position":4,"cik":"0001577650","reported_name":"Celgene European Investment Co LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-01-31T08:39:40.000Z","date":"2018-01-23","kind":"purchase","acquired":true,"shares":851154,"price":67,"value":57027318.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"This Form 4 Amendment is being submitted to correct the date of earliest transaction in box 3 to reflect January 23, 2018."}],"balance_after":1374599,"source":{"system":"sec-edgar","filing":"0001209191-18-006131","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919118006131/doc4a.xml","form_type":"4/A","original_submission_date":"2018-01-23"}},{"id":4092965,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153827,"kind":"organization","name":"Celgene Switzerland LLC","position":2,"cik":"0001661486","reported_name":"Celgene Switzerland LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153828,"kind":"organization","name":"Celgene Alpine Investment Co., LLC","position":3,"cik":"0001581774","reported_name":"Celgene Alpine Investment Co., LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153826,"kind":"organization","name":"Celgene European Investment Co LLC","position":4,"cik":"0001577650","reported_name":"Celgene European Investment Co LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-01-23T16:35:54.000Z","date":"2018-01-23","kind":"purchase","acquired":true,"shares":851154,"price":67,"value":57027318.0,"ownership":{"direct":true},"balance_after":1374599,"source":{"system":"sec-edgar","filing":"0001209191-18-004895","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919118004895/doc4.xml","form_type":"4"}},{"id":4347043,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":153826,"kind":"organization","name":"Celgene European Investment Co LLC","position":1,"cik":"0001577650","reported_name":"Celgene European Investment Co LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153827,"kind":"organization","name":"Celgene Switzerland LLC","position":2,"cik":"0001661486","reported_name":"Celgene Switzerland LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153828,"kind":"organization","name":"Celgene Alpine Investment Co., LLC","position":3,"cik":"0001581774","reported_name":"Celgene Alpine Investment Co., LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":4,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-04-24T16:34:16.000Z","date":"2017-04-24","kind":"purchase","acquired":true,"shares":624575,"price":49.5,"value":30916462.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Of these shares, 624,575 shares are owned directly by Celgene Switzerland LLC (\"Celgene Switzerland\"), 708,333 shares are owned directly by Celgene Alpine Investment Co. LLC (\"Celgene Alpine\"), each a wholly-owned subsidiary of Celgene Corporation (\"Celgene\"), and Celgene has the power to vote, acquire, hold and dispose of all such shares.  Celgene and Celgene European Investment Company LLC, a wholly owned subsidiary of Celgene (\"CEICO\"), disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.  The remaining 523,445 shares are owned directly by Celgene.  CEICO, Celgene Switzerland and Celgene Alpine disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":1856353,"source":{"system":"sec-edgar","filing":"0001209191-17-027983","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919117027983/doc4.xml","form_type":"4"}},{"id":4474307,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":153827,"kind":"organization","name":"Celgene Switzerland LLC","position":1,"cik":"0001661486","reported_name":"Celgene Switzerland LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":2,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2017-02-01T16:18:28.000Z","date":"2017-02-01","kind":"exercise","acquired":false,"shares":10448100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series B-1 Preferred Stock automatically converted into 0.271 share of Common Stock without payment of further consideration. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series B-1 Preferred Stock automatically converted into 0.271 share of Common Stock without payment of further consideration. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series B-1 Preferred Stock automatically converted into 0.271 share of Common Stock without payment of further consideration. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are owned directly by Celgene Switzerland LLC, a wholly-owned subsidiary of Celgene Corporation (\"Celgene\"), and Celgene has the power to vote, acquire, hold and dispose of all shares. Celgene disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2831463},"source":{"system":"sec-edgar","filing":"0001209191-17-006676","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919117006676/doc4.xml","form_type":"4"}},{"id":4474306,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":153827,"kind":"organization","name":"Celgene Switzerland LLC","position":1,"cik":"0001661486","reported_name":"Celgene Switzerland LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":2,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-02-01T16:18:28.000Z","date":"2017-02-01","kind":"purchase","acquired":true,"shares":625000,"price":16,"value":10000000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are owned directly by Celgene Switzerland LLC, a wholly-owned subsidiary of Celgene Corporation (\"Celgene\"), and Celgene has the power to vote, acquire, hold and dispose of all shares. Celgene disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein."}],"balance_after":3456463,"source":{"system":"sec-edgar","filing":"0001209191-17-006676","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919117006676/doc4.xml","form_type":"4"}},{"id":4474305,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":153827,"kind":"organization","name":"Celgene Switzerland LLC","position":1,"cik":"0001661486","reported_name":"Celgene Switzerland LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":2,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-02-01T16:18:28.000Z","date":"2017-02-01","kind":"exercise","acquired":true,"shares":2831463,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series B-1 Preferred Stock automatically converted into 0.271 share of Common Stock without payment of further consideration. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are owned directly by Celgene Switzerland LLC, a wholly-owned subsidiary of Celgene Corporation (\"Celgene\"), and Celgene has the power to vote, acquire, hold and dispose of all shares. Celgene disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein."}],"balance_after":2831463,"source":{"system":"sec-edgar","filing":"0001209191-17-006676","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000120919117006676/doc4.xml","form_type":"4"}}]}